Navigation Links
E. coli engineered to produce important class of antibiotic, anti-cancer drugs
Date:12/22/2008

Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have taken a major step forward in the field of metabolic engineering, successfully using the bacterium Escherichia coli to synthesize a class of natural products known bacterial aromatic polyketides, which include important antibiotic and anticancer drugs.

Natural products are pharmacologically or biologically potent chemical compounds produced by living organisms; many are the active ingredients in pharmaceuticals. Bacterial aromatic polyketides include the antibiotic tetracycline and the compound doxorubicin, used in the treatment of breast and other cancers.

Because many of these natural products are synthesized by organisms that are difficult to collect, grow and maintain, researchers have sought to produce them using simpler organisms like E. coli, whose fast growth, variety of genetic tools and well-understood metabolism make it an ideal host for engineering and mass producing these compounds.

While turning E. coli into a microbial factory for natural products has been highly successful, resulting in the production of groups of drugs that include antibiotics like erythromycin and vancomycin, as well as terpenes and alkaloids, attempts to synthesize bacterial aromatic polyketides had previously been hindered by the compounds' complicated assembly process.

To achieve the successful synthesis of the aromatic polyketides, the UCLA research team which included principal investigator Yi Tang, an associate professor of chemical and biomolecular engineering, and graduate students Wenjun Zhang and Yanran Li first dissected a polyketide synthase enzyme from a rice plant fungus, then reassembled it and transferred it into the E. coli bacterium. The resulting synthetic enzyme is necessary to synthesize the carbon backbone of aromatic polyketides, which was previously inaccessible in E. coli.

In addition to the synthetic enzyme, the researchers introduced other enzymes to form a new pathway in E. coli that produced a range of bacterial aromatic polyketides from simple nutrients such as glucose.

"This is a key advance in the field of natural product biosynthesis," said Tang of the research, which will be published Dec. 30 in Proceedings of the National Academy of Sciences and is currently available on the journal's website. "We have now outfitted E. coli with the ability to make this family of compounds that are vital toward treating diseases such as infectious diseases and cancer.

"Furthermore, we can now take advantage of the E. coli machinery to engineer the pathways we introduced and synthesize new versions of natural products that may be more potent than the current versions - so-called unnatural natural products."

On a more fundamental level, the UCLA researchers are exploring interactions between the bacterial and fungal components they introduced into E. coli, which are from different kingdoms of life.

"There are some beliefs that bacterial and fungal enzymes will not cross-talk to each other," said Zhang, the paper's lead author. "Our work showed that polyketide synthase from the two kingdoms can indeed be functionally combined inside the E. coli platform. Therefore, there is much to learn about why these interactions are possible."


'/>"/>

Contact: Matthew Chin
mchin@support.ucla.edu
310-206-0680
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
2. T vs. B: Re-engineered human T cells effectively target and kill cancerous B cells
3. 5,000 Patients Treated With OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
4. Nanomedicine system engineered to enhance therapeutic effects of injectable drugs
5. Reconstructing mandibular defects with bioengineered tooth and bone
6. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
7. OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
8. Tumor suppressor genes speed up and slow down aging in engineered mouse
9. FDA Proposes Regulations for Genetically Engineered Animals
10. Top Athletes Join Forces for a New Mission: Athlete-Engineered Skincare to Support Performance and Benefit Charity
11. Whiplash may produce delayed jaw pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics ... 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme ... on Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over ... The 5k Run and Walk and 1-mile walk were held to increase awareness ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... PA (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the ... Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016 The ... USD 2.06 billion by 2022, according to a ... consumer awareness towards a healthy lifestyle is expected ... years.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... with rising health treatment expenditure has urged consumers ...
(Date:4/26/2016)... Mich. , April 26, 2016 Diplomat ... promotion of Jennifer Hagerman , Pharm D., to ... her growing role at Diplomat, Hagerman will continue to ... the company that delivers custom education and training to ... the specialty pharmacy industry. Diplomat University also houses the ...
(Date:4/26/2016)... , April 26, 2016 US demand ... to expand 4.9 percent annually to $27.6 billion ... healthcare facilities to decrease rates of healthcare-associated infections ... supplies, equipment, and services.  Although declining, the overall ... above targeted levels set by the CDC.  Recent ...
Breaking Medicine Technology: